Author:
Franchini Massimo,Focosi Daniele
Publisher
Springer Berlin Heidelberg
Reference63 articles.
1. Ali S, Luxmi S, Anjum F, Muhaymin SM, Uddin SM, Ali A et al (2020) Hyperimmune anti-COVID-19 IVIG (C-IVIG) therapy for passive immunization of severe and critically ill COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial. Trials 21(1):905
2. Ali SO, Takas T, Nyborg A, Shoemaker K, Kallewaard NL, Chiong R et al (2018) Evaluation of MEDI8852, an anti-influenza A monoclonal antibody, in treating acute uncomplicated influenza. Antimicrob Agents Chemother 62(11)
3. Beigel JH (2018) Polyclonal and monoclonal antibodies for the treatment of influenza. Curr Opin Infect Dis 31(6):527–534
4. Bermingham A, Chand MA, Brown CS, Aarons E, Tong C, Langrish C et al (2012) Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro Surveill Bulletin European sur les maladies transmissibles = Eur Commun Dis Bull 17(40):20290
5. Bimler L, Kim T, Ronzulli SL, Song AY, Johnson SK, Jones CA et al (2022) M2e-specific monoclonal antibody cocktails against influenza A virus are superior to individual monoclonal antibody treatments, universally effective, and viral escape mutant resistant. bioRxiv 2022.04.02.486847. A low-dose triple antibody cocktail against the ectodomain of the matrix protein 2 of influenza A is a universally effective and viral escape mutant resistant therapeutic agent. bioRxiv